이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

BEACON-AA: 심방세동과 뇌동맥경화증을 동반한 뇌졸중 환자에서 클로피도그렐과 병용 또는 단독 사용하는 아픽사반

2026년 11월 15일 업데이트: Yonsei University

심방세동과 뇌동맥경화증 환자에서 재발성 허혈성 뇌졸중 예방에 대한 아픽사반과 클로피도그렐의 효능을 평가하기 위한 다기관 전향적 무작위 연구

This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30 (±5) days compared with baseline MRI, adjudicated by a central committee.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Although oral anticoagulants are effective in preventing cardioembolic stroke in patients with non-valvular atrial fibrillation (NVAF), a considerable proportion of ischemic strokes in these patients are caused by concomitant large artery atherosclerosis. Carotid or intracranial artery stenosis is present in a substantial number of patients with NVAF and is associated with a higher risk of recurrent cerebral infarction despite standard anticoagulation. In such patients, adding an antiplatelet agent to oral anticoagulation may theoretically reduce atherothrombotic events, but it also raises concern for increased bleeding risk. Recent clinical evidence on this issue remains limited, and the optimal antithrombotic strategy for patients with NVAF and coexisting symptomatic atherosclerotic stenosis has not been clearly established.

The BEACON-AA trial is a multicenter, randomized, open-label, blinded-endpoint (PROBE) study designed to compare the safety and efficacy of apixaban monotherapy versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation (NVAF) and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomized in a 1:1 ratio to receive apixaban alone or apixaban plus clopidogrel for 30 days, followed by apixaban monotherapy thereafter.

Brain MRI including diffusion-weighted and FLAIR sequences will be performed at baseline and at 30 ± 5 days to assess new or recurrent ischemic lesions. The primary efficacy outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee. Secondary efficacy outcomes include: 1) incidence of symptomatic ischemic stroke or transient ischemic attack within 90 days, 2) incidence of acute coronary syndrome within 90 days,3) cardiovascular mortality within 90 days, 4) composite major cardiovascular events within 90 days, 5) all-cause mortality within 90 days, 6) proportion of patients with modified Rankin Scale (mRS) 0-2 at 90 days, and 7) proportion of patients with mRS 0-3 at 90 days. The primary safety outcomes are: 1) incidence of major bleeding within 90 days, defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and 2) incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE)) at 30 ± 5 days after randomization. All imaging and clinical events will be independently adjudicated by blinded central adjudication committees.

연구 유형

중재적

등록 (추정된)

586

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Young Dae Kim, M.D. Ph.D.
  • 전화번호: 02-2228-1619
  • 이메일: NEURO05@YUHS.AC

연구 장소

      • Busan, 대한민국
        • 모병
        • Pusan National University Hospital
        • 연락하다:
          • Han-Jin Cho, Professor
          • 전화번호: '+82--51-240-7000
          • 이메일: chohj75@gmail.com
      • Busan, 대한민국
        • 모병
        • Dong-A University Hospital
        • 연락하다:
      • Chuncheon, 대한민국
        • 모병
        • Hallym University Chuncheon Sacred Heart Hospital
        • 연락하다:
      • Daegu, 대한민국
        • 모병
        • Keimyung University Dongsan Hospital
        • 연락하다:
      • Goyang, 대한민국
        • 모병
        • National Health Insurance Service Ilsan Hospital
        • 연락하다:
      • Incheon, 대한민국
        • 모병
        • Inha University Hospital
        • 연락하다:
      • Incheon, 대한민국
        • 모병
        • Gachon University Gil Medical Center
        • 연락하다:
          • Sang Hee Ha, Professor
          • 전화번호: +82-1577-2299
          • 이메일: shha31@naver.com
      • Incheon, 대한민국
        • 모병
        • Catholic Kwandong University International St. Mary's Hospital
        • 연락하다:
      • Seoul, 대한민국
        • 모병
        • Samsung Medical Center
        • 연락하다:
      • Seoul, 대한민국
        • 모병
        • Seoul National University Hospital
        • 연락하다:
          • Keun-Hwa Jung, Professor
          • 전화번호: +82-1588-5700
          • 이메일: jungkh@gmail.com
      • Seoul, 대한민국
        • 모병
        • Korea University Anam Hospital
        • 연락하다:
      • Seoul, 대한민국
        • 모병
        • Kangbuk Samsung Hospital
        • 연락하다:
      • Seoul, 대한민국
        • 모병
        • Ewha Womans University Seoul Hospital
        • 연락하다:
      • Seoul, 대한민국
        • 모병
        • Gangnam Severance Hospital
        • 연락하다:
          • Yo Han Jung, Professor
          • 전화번호: +82-1599-6114
          • 이메일: YHJUNG@yuhs.ac
      • Seoul, 대한민국
        • 모병
        • Hanyang University Seoul Hospital
        • 연락하다:
      • Seoul, 대한민국
        • 모병
        • Kyung Hee University Hospital
        • 연락하다:
      • Seoul, 대한민국
        • 모병
        • Kyung Hee University Hospital at Gangdong
        • 연락하다:
          • Il Hyung Lee, Professor
          • 전화번호: +82-1577-5800
          • 이메일: neu210@naver.com
      • Seoul, 대한민국
        • 모병
        • Inje University Sanggye Paik Hospital
        • 연락하다:
      • Seoul, 대한민국
        • 모병
        • Kangdong Sacred Heart Hospital
        • 연락하다:
      • Seoul, 대한민국
        • 모병
        • Yonsei University College of Medicine
        • 연락하다:
          • Young Dae Kim, Professor
          • 전화번호: +82-2-2228-1619
          • 이메일: NEURO05@YUHS.AC
      • Yŏngin, 대한민국
        • 모병
        • Yongin Severance Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

19년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Adults aged 19 years or older at the time of enrollment.

  2. Patients with non-valvular atrial fibrillation (NVAF) documented by electrocardiography.

  3. Acute ischemic stroke confirmed by brain MRI (diffusion-weighted and FLAIR sequences), with last known well within 120 hours prior to randomization.

  4. Presence of clinically significant atherosclerosis in the cerebral or aortic arteries, meeting at least one of the following criteria:

    ① ≥30% stenosis in the relevant artery (the artery supplying the infarcted territory) demonstrated by CTA, MRA, or DSA - using the WASID criteria for intracranial arteries and NASCET criteria for extracranial arteries.

    ② High-risk atherosclerotic plaque features in the relevant artery demonstrated by CTA, MRA, or ultrasound, such as ulceration, intraplaque hemorrhage, mobile plaque, or a large lipid core (involving ≥25% of plaque cross-sectional area) on CTA/MRA, or ulceration, mobile plaque, or hypoechoic/echolucent plaque on ultrasound; or presence of branch artery occlusive disease (BAOD).

    ③ Complex aortic plaque (≥4 mm in thickness, mobile, or ulcerative) identified in the ascending aorta or aortic arch by transthoracic/transesophageal echocardiography or coronary CT angiography.

  5. Written informed consent provided by the participant or a legally authorized representative.

Exclusion Criteria:

  1. Presence of mechanical heart valves or rheumatic mitral stenosis.
  2. Requirement for antithrombotic agents other than apixaban and clopidogrel.
  3. Planned percutaneous coronary intervention, coronary artery bypass graft surgery, carotid endarterectomy, or intracranial stenting within 3 months after enrollment.
  4. Presence of mural thrombus in the heart confirmed by imaging.
  5. Renal impairment with creatinine clearance ≤25 mL/min.
  6. Severe hepatic impairment, including acute hepatitis, chronic active hepatitis, hepatic lesions or coagulopathy, hepatic failure, or laboratory evidence of AST/ALT >2× the upper limit of normal (ULN) or total bilirubin ≥1.5× ULN.
  7. Small-vessel occlusion (lacunar infarction) according to the TOAST classification.
  8. History within the past 30 days of gastrointestinal bleeding, vascular malformation of the brain or spinal cord, recent brain, spinal, or ophthalmologic surgery or trauma, esophageal varices, or intracranial hemorrhage at any time; or chronic regular use of NSAIDs (≥3 days per week for ≥2 consecutive weeks).
  9. Ischemic stroke occurring despite concurrent use of both NOAC and antiplatelet therapy.
  10. Planned surgery or high-bleeding-risk procedure within 3 months, or presence of active bleeding at enrollment.
  11. Anemia (hemoglobin < 8.0 g/dL) or thrombocytopenia (platelet count < 100,000/µL).
  12. Pre-stroke modified Rankin Scale (mRS) ≥ 2.
  13. Severe comorbid illness or malignancy not in complete remission with an expected life expectancy <1 year.
  14. Known hypersensitivity or allergy to apixaban or clopidogrel.
  15. Pregnant or breastfeeding women.
  16. Uncontrolled diabetes mellitus (HbA1c > 10.0%) or severe hypertension (systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg).
  17. Concomitant use of strong CYP3A4 and P-glycoprotein inhibitors that can significantly increase apixaban exposure (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin).
  18. Concomitant use of strong CYP2C19 inducers that can enhance clopidogrel antiplatelet effect and increase bleeding risk (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort).
  19. Clinically significant mass effect due to space-occupying cerebral infarction, or patients expected to require decompressive craniectomy, including those with midline shift > 5 mm, loss of basal cisterns, herniation, fourth-ventricle compression, or obstructive hydrocephalus in posterior fossa infarcts.
  20. Intracranial hemorrhage or hemorrhagic transformation (PH1 or PH2) according to ECASS criteria.
  21. Participation in another interventional clinical trial within the past 30 days or concurrent participation in another interventional study (non-interventional observational or registry studies may be allowed at the investigator's discretion).
  22. Any other condition that, in the investigator's judgment, would make participation or continued involvement in the study inappropriate or infeasible.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Apixaban and Clopidogrel Combination Therapy

Participants receive apixaban(5mg twice daily, or 2.5mg twice daily if indicated) plus clopidogrel 75mg daily for 30days, followed by apixaban monotherapy thereafter.

Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.

다른 이름들:
  • 엘리퀴스

Clopidogrel 75mg once daily for 30 days in combination with apixaban, then discontinued.

다른 이름들:
  • 플라빅스
활성 비교기: Apixaban Monotherapy

Participants receive apixaban 5mg(or 2.5mg if indicated) twice daily as monotherapy for 30 days and continue apixaban monotherapy thereafter.

Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.

다른 이름들:
  • 엘리퀴스

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee
기간: At 30 ± 5 days after randomization

New ischemic lesions, either symptomatic or asymptomatic, identified on DWI/FLAIR at 30 (±5) days compared with baseline MRI, as adjudicated by a central adjudication committee.

At 30 ± 5 days after randomization

2차 결과 측정

결과 측정
측정값 설명
기간
Incidence of symptomatic ischemic stroke or transient ischemic attack (TIA)
기간: Within 90 days after randomization

Occurrence of new symptomatic ischemic stroke or transient ischemic attack confirmed by clinical and/or imaging criteria.

Within 90 days after randomization
Incidence of acute coronary syndrome (ACS)
기간: Within 90 days after randomization

Occurrence of acute coronary syndrome, including unstable angina or myocardial infarction, confirmed by standard diagnostic criteria.

Within 90 days after randomization
Cardiovascular mortality
기간: Within 90 days after randomization

Death due to fatal stroke, fatal myocardial infarction, or sudden death not clearly attributed to non-vascular causes.

Within 90 days after randomization
Composite major cardiovascular events
기간: Within 90 days after randomization

Composite of recurrent stroke (ischemic or hemorrhagic), acute coronary syndrome, or cardiovascular death.

Within 90 days after randomization
All-cause mortality
기간: Within 90 days after randomization

Death from any cause during the 90-day follow-up period.

Within 90 days after randomization
Proportion of patients with modified Rankin Scale (mRS) score 0-2
기간: At 90 days after randomization

Functional independence defined as mRS score of 0-2 at day 90.

At 90 days after randomization
Proportion of patients with modified Rankin Scale (mRS) score 0-3
기간: At 90 days after randomization

Favorable functional outcome defined as mRS score of 0-3 at day 90.

At 90 days after randomization
Incidence of major bleeding events according to the ISTH criteria
기간: Within 90 days after randomization

Major bleeding events defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria, including fatal bleeding, symptomatic intracranial hemorrhage, intraocular bleeding causing vision loss, bleeding resulting in inability to perform usual activities, bleeding requiring transfusion of ≥2 units of whole blood or red cells, or bleeding leading to hospitalization.

Within 90 days after randomization
Incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE))
기간: At 30 ± 5 days after randomization

Newly developed asymptomatic cerebral hemorrhages identified on MR-Diffusion/FLAIR/SWI(or GRE) performed 30 ± 5 days after randomization.

At 30 ± 5 days after randomization

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 7월 14일

기본 완료 (추정된)

2029년 7월 1일

연구 완료 (추정된)

2029년 8월 31일

연구 등록 날짜

최초 제출

2025년 11월 14일

QC 기준을 충족하는 최초 제출

2025년 11월 14일

처음 게시됨 (실제)

2025년 11월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 15일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 4-2025-0697

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .